leucyl-glycine-β-naphthylamide | 100930-00-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: leucyl-glycine-β-naphthylamide
• 英文别名: L-leucylglycine 2-naphthylamide；(2S)-2-amino-4-methyl-N-[2-(naphthalen-2-ylamino)-2-oxoethyl]pentanamide
• CAS: 100930-00-5
• 化学式: C₁₈H₂₃N₃O₂
• mdl: MFCD00056604
• 分子量: 313.4
• InChiKey: REBHTGLALGGOMA-INIZCTEOSA-N

物化性质

• 沸点：
  605.0±40.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  在常温常压下保持稳定，应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  84.2
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S36
• 危险类别码：
  R40
• 危险标志：
  GHS08
• 危险性描述：
  H351
• 危险性防范说明：
  P281
• 储存条件：
  密封储存，应存放在阴凉、干燥的库房中。冷藏时，请将温度控制在-20°C。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
: Leu-Gly β-naphthylamide
Product name
CAS-No. : 100930-00-5

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Carcinogenicity (Category 2)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Limited evidence of a carcinogenic effect.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
Suspected of causing cancer.
Precautionary statement(s)
Use personal protective equipment as required.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R40 Limited evidence of a carcinogenic effect.
S-phrase(s)
S22 Do not breathe dust.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C18H23N3O2
Molecular Weight : 313,39 g/mol
Component Concentration
Leu-Gly β-naphthylamide
CAS-No. 100930-00-5 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
These chronic effects are suggested from analogy to beta-naphthylamine, RTECS# QM2100000.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
Limited evidence of carcinogenicity in animal studies
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
These chronic effects are suggested from analogy to beta-naphthylamine, RTECS# QM2100000.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

H-Leu-Gly-βNA可以用作底物来检测N-乙酰-B-D-氨基半乳糖酶的存在与否[1]。

反应信息

• 作为反应物：
  描述：

  leucyl-glycine-β-naphthylamide 在 水 作用下， 反应 1.0h， 生成 L-亮氨酰甘氨酸 、 2-萘胺
  参考文献：
  名称：

  Presence of a dipeptidyl aminopeptidase III in Saccharomyces cerevisiae.

  摘要：

  研究发现，酿酒酵母细胞提取物的可溶性部分含有对精氨酰-精氨酰-β-萘甲酰胺（Arg-Arg-βNA）的水解活性。通过二乙氨基乙基（DEAE）-纤维素柱层析法去除了大部分污染性 Arg-βNA 水解活性，并部分纯化了该酶。它的各种特性与哺乳动物的二肽基氨基肽酶 III（DAP III）非常相似，但在某些方面略有不同。

  DOI：

  10.1248/cpb.38.246

文献信息

• Reagent for testing periodontal diseases
  申请人：SUNSTAR KABUSHIKI KAISHA

  公开号：EP0255341A2

  公开（公告）日：1988-02-03

  A reagent for testing periodontal diseases which diagnoses or prognosticates contraction or progress of said diseases by determining aminopeptidase-like enzymatic activity in a specimen, said reagent comprises as a substrate for the enzyme either or both compounds of the formula: X-Z-Arg-Y [1] wherein Arg is arginine residue; X is hydrogen or an amino blocking group; Y is a color developing group attached to the C-terminal of Arg; and Z is an amino acid or peptide residue composed of 1 to 4 amino acids or their blocked derivatives, the C-terminal of which is attached to the N-­terminal of Arg, and Xʹ-Zʹ-Pro-Yʹ [2] wherein Pro is proline residue; Xʹ is hydrogen or an amino blocking group; Yʹ is a color developing group attached to the C-terminal of Pro; and Zʹ is an amino acid or peptide residue composed of 0 to 4 amino acids or their blocked derivatives, the C-terminal of which is attached to the N-­terminal of Pro.

  一种检测牙周疾病的试剂，它通过测定标本中氨基肽酶样酶的活性来诊断或预测所述疾病的收缩或进展，所述试剂包括作为酶底物的式中的一种或两种化合物： X-Z-Arg-Y [1] 其中 Arg 是精氨酸残基；X 是氢或氨基封端基；Y 是连接到 Arg C 端的显色基团；Z 是由 1 至 4 个氨基酸或其封端衍生物组成的氨基酸或肽残基，其 C 端连接到 Arg 的 N 端，以及 Xʹ-Zʹ-Pro-Yʹ[2］ 其中Pro是脯氨酸残基；Xʹ是氢或氨基封端基；Yʹ是连接到Pro的C-末端的显色基团；Zʹ是由0至4个氨基酸或其封端衍生物组成的氨基酸或肽残基，其C-末端连接到Pro的N-末端。
• US4874695A
  申请人：——

  公开号：US4874695A

  公开（公告）日：1989-10-17
• US5137811A
  申请人：——

  公开号：US5137811A

  公开（公告）日：1992-08-11